Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 34, Issue 12, 2016, Pages 1339-1344

  Blauwhoff Buskermolen, Susanne ^a   Versteeg, Kathelijn S ^a   De Van Der Schueren, Marian A E ^a,b   Den Braver, Nicole R ^a   Berkhof, Johannes ^a   Langius, Jacqueline A E ^b,c   Verheul, Henk M W ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HAN UNIVERSITY OF APPLIED SCIENCES   (Netherlands)

^c THE HAGUE UNIVERSITY OF APPLIED SCIENCES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MUSCLE MASS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SKELETAL MUSCLE; SURVIVAL RATE; THERAPY DELAY; THIRD LUMBAR VERTEBRA; WEIGHT CHANGE; BODY WEIGHT; CACHEXIA; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; COMPLICATION; DISEASE COURSE; DRUG EFFECTS; HEALTH STATUS; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; MUSCLE ATROPHY; PALLIATIVE THERAPY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; CACHEXIA; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HEALTH STATUS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NEOPLASM METASTASIS; PALLIATIVE CARE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84963569431     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.6043     Document Type: Article

References (39)

1. World Health Organization International Agency for Research on Cancer: GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr
2. Barret M, Antoun S, Dalban C, et al: Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer 66: 583-589, 2014
3. Thoresen L, Frykholm G, Lydersen S, et al: Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma: Different assessment criteria for nutritional status provide unequal results. Clin Nutr 32:65-72, 2013
4. Barret M, Malka D, Aparicio T, et al: Nutritional status affects treatment tolerability and survival in metastatic colorectal cancer patients: Results of an AGEO prospective multicenter study. Oncology 81: 395-402, 2011
5. Tan BHL, Birdsell LA, Martin L, et al: Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 15:6973-6979, 2009
6. Prado CMM, Lieffers JR, McCargar LJ, et al: Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol 9:629-635, 2008
7. Fearon K, Strasser F, Anker SD, et al: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 12:489-495, 2011
8. Lieffers JR, Mourtzakis M, Hall KD, et al: A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: Contributions of organ and tumor mass to whole-body energy demands. Am J Clin Nutr 89:1173-1179, 2009
9. Prado CM, Sawyer MB, Ghosh S, et al: Central tenet of cancer cachexia therapy: Do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr 98:1012-1019, 2013
10. Wallengren O, Iresjö B, Lundholm K, et al: Loss of muscle mass in the end of life in patients with advanced cancer. Support Care Cancer 23:79-86, 2015
11. Prado CMM, Baracos VE, McCargar LJ, et al: Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13:3264-3268, 2007
12. Van Vledder MG, Levolger S, Ayez N, et al: Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg 99:550-557, 2012
13. Malietzis G, Aziz O, Bagnall NM, et al: The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes: A systematic review. Eur J Surg Oncol 41:186-196, 2015
14. Blauwhoff-Buskermolen S, De Van Der Schueren MA, Verheul HM, et al: "Pre-cachexia": A non-existing phenomenon in cancer? Ann Oncol 25: 1668-1669, 2014
15. Shen W, Punyanitya M, Wang Z, et al: Total body skeletal muscle and adipose tissue volumes: Estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 97:2333-2338, 2004
16. Mourtzakis M, Prado CMM, Lieffers JR, et al: A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33:997-1006, 2008
17. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, et al: Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol (1985) 85: 115-122, 1998
18. MacDonald AJ, Greig CA, Baracos V: The advantages and limitations of cross-sectional body composition analysis. Curr Opin Support Palliat Care 5:342-349, 2011
19. Awad S, Tan BH, Cui H, et al: Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr 31: 74-77, 2012
20. Prado CMM, Bekaii-Saab T, Doyle LA, et al: Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: Selumetinib in patients with cholangiocarcinoma. Br J Cancer 106:1583-1586, 2012
21. Sabel MS, Lee J, Cai S, et al: Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol 18:3579-3585, 2011
22. Antoun S, Lanoy E, Iacovelli R, et al: Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer 119:3377-3384, 2013
23. Martin L, Birdsell L, Macdonald N, et al: Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31:1539-1547, 2013
24. Frank E, Dunlop AL: What does a patient's outfit weight? Fam Med 32:595-596, 2000
25. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
26. Frontera WR, Hughes VA, Fielding RA, et al: Aging of skeletal muscle: A 12-yr longitudinal study. J Appl Physiol (1985) 88:1321-1326, 2000
27. Landi F, Liperoti R, Russo A, et al: Sarcopenia as a risk factor for falls in elderly individuals: Results from the ilSIRENTE study. Clin Nutr 31:652-658, 2012
28. Janssen I, Heymsfield SB, Ross R: Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 50:889-896, 2002
29. Rolland Y, Czerwinski S, Abellan Van Kan G, et al: Sarcopenia: Its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging 12:433-450, 2008
30. Cassidy J, Clarke S, Díaz-Rubio E, et al: XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 105:58-64, 2011
31. Prado CMM, Baracos VE, McCargar LJ, et al: Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:2920-2926, 2009
32. Sjøblom B, Grønberg BH, Benth JS, et al: Low muscle mass is associated with chemotherapyinduced haematological toxicity in advanced nonsmall cell lung cancer. Lung Cancer 90:85-91, 2015
33. Stene GB, Helbostad JL, Amundsen T, et al: Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol 54:340-348, 2015
34. Speck RM, Courneya KS, Masse LC, et al: An update of controlled physical activity trials in cancer survivors: A systematic review and meta-analysis. J Cancer Surviv 4:87-100, 2010
35. Courneya KS, Segal RJ, Mackey JR, et al: Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: A multicenter randomized controlled trial. J Clin Oncol 25:4396-4404, 2007
36. Paddon-Jones D, Leidy H: Dietary protein and muscle in older persons. Curr Opin Clin Nutr Metab Care 17:5-11, 2014
37. Paddon-Jones D, Rasmussen BB: Dietary protein recommendations and the prevention of sarcopenia. Curr Opin Clin Nutr Metab Care 12:86-90, 2009
38. Fearon K, Arends J, Baracos V: Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 10:90-99, 2013
39. Zhang H, Garcia JM: Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. Expert Opin Pharmacother 16:1245-1253, 2015